Lifecare (LIFE:NASDAQ) Investor Relations Material

Overview

San Diego-based biotherapeutics company aTyr Pharma is focused on discovering and developing novel immunological pathways for the creation of new medicines. Its lead candidate, efzofitimod, is currently in Phase III clinical trials for the treatment of pulmonary sarcoidosis and in Phase 1b/2a clinical trials for other interstitial lung diseases, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody for the treatment of solid tumors in preclinical development. aTyr Pharma has a collaboration and license agreement with Kyorin Pharmaceutical for the development and commercialization of efzofitimod for ILDs in Japan. The company was founded in 2005.

Frequently Asked Questions

What is Lifecare's ticker?

Lifecare's ticker is LIFE

What exchange is Lifecare traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Lifecare's headquarters?

They are based in San Diego, California

How many employees does Lifecare have?

There are 51-200 employees working at Lifecare

What is Lifecare's website?

It is lifecare.no

What type of sector is Lifecare?

Lifecare is in the Healthcare sector

What type of industry is Lifecare?

Lifecare is in the Biotechnology industry

Who are Lifecare's peers and competitors?

The following five companies are Lifecare's industry peers:

- Vanda Pharmaceuticals

- Innate Pharma S.A.

- argenx SE

- Aridis Pharmaceuticals Inc.

- Revance Therapeutics